Hemophilia is also a relatively common disease, and it is essential for hemophiliacs to understand the treatment of hemophilia. What kind of treatment is used for hemophilia patients and what are the treatment methods. There are three main treatments for hemophilia in this: 1. First, there are local hemostatic methods. If local compression of a site is effective in stopping bleeding, gauze or cotton balls plus thrombin and epinephrine wraps can be used for compression. Foreign also used other, like hemostatic drugs added to the gauze. Joint cavity bleeding, try to cold compress and brake, to a certain time, after 24 hours, you can apply hot compress; 2, replacement therapy, hemophilia patients are mainly clotting factor deficient, if it is determined which clotting factor, that is, which hemophilia, to be transfused until the activity of clotting factors to a certain level, in order to prevent bleeding. So coagulation factor replacement therapy has plasma transfusion as the preferred method for mild AB hemophilia, but it is somewhat limited because of the large volume. The second is cold precipitation, which is a coagulation factor isolated from fresh frozen plasma and has the advantage of being relatively small compared to fresh frozen plasma. Therefore, it is suitable for patients with poor organ function, especially heart function, and is suitable for patients with light, heavy and intermediate forms of hemophilia. The third is the quality of factor VIII and factor IX concentrates, which are lyophilized products for targeting clotting factor deficiency. One unit is equivalent to 1 ml of fresh frozen plasma, so one unit can increase the activity in the body, 2% for factor VIII and 0.5%-1% for factor IX. Because the half-life of factor VIII and factor IX are different, the half-life of factor VIII and factor IX in the body is relatively short, so it is supplemented once every 12 hours to maintain a relatively high level of factors and control bleeding. The fourth thrombospondin complex is 200 units per vial, which is equivalent to factor IX in 200 ml of plasma, so it is especially suitable for hemophilia B, which is hemophilia I. The main advantage of recombinant human coagulation factor is that it is not contaminated by virus and it is a recombinant product, while the factor VIII and factor IX mentioned earlier are isolated from plasma, which may have the possibility of virus contamination and cause possible side effects of viral hepatitis or other viral infections. Therefore, the recombinant human factor is widely used in clinical practice; 3. UA therapy, DDAVP is 1-deamino-8-dextro-arginine pressin, which used to be diuretic in effect, but it can enhance the level of factor VIII and promote the release of factor VIII after use, but it is mainly suitable for light hemophilia patients, while for heavy patients, it is necessary to infuse coagulation factors or supplement fresh blood. However, it is emphasized that it is mainly suitable for patients with mild hemophilia. These three treatments for hematologic diseases are relatively common and their effects are clear, so I believe that these supports can be helpful for hemophiliacs.